Form 4: BioXcel Therapeutics Director Converts Restricted Stock Units to Common Shares

BioXcel Therapeutics Director David J. Mack converted 1,693 Restricted Stock Units into common stock, increasing his direct beneficial ownership of common shares to 11,851.

Summary

• David J. Mack, a Director of BioXcel Therapeutics, Inc. (BTAI), reported a transaction on May 31, 2025, involving the conversion of equity awards.
• He acquired 1,693 shares of BioXcel Therapeutics Common Stock through the exercise or conversion of derivative securities.
• Concurrently, 1,693 Restricted Stock Units (RSUs) were disposed of as they were converted into common stock.
• The transaction price for the RSU conversion was $0.
• Following this reported transaction, Mr. Mack directly beneficially owns 11,851 shares of BioXcel Therapeutics Common Stock.
• He also directly beneficially owns 8,466 Restricted Stock Units.
• The RSUs involved were part of a grant of 20,317 units received on November 21, 2024, which vest in twelve equal monthly installments beginning November 30, 2024, contingent on his continued service as a Director.

Sentiment

Score: 7

Explanation: The filing indicates a routine conversion of Restricted Stock Units into common stock by a director, which is a standard compensation event. The increase in direct common stock ownership by an insider is generally viewed as a positive signal of alignment with shareholder interests, though it's a pre-scheduled event.

Positives

• Director David J. Mack increased his direct beneficial ownership of BioXcel Therapeutics common stock to 11,851 shares, which can be viewed as a positive signal of continued alignment with shareholder interests.

Future Outlook

The remaining 8,466 Restricted Stock Units held by Director David J. Mack are expected to continue vesting in equal monthly installments, subject to his continued service as a Director through the vesting period.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction related to equity compensation and does not provide broader industry context or trends. It reflects an individual director's ownership changes within BioXcel Therapeutics.

Stakeholder Impact

• Shareholders: The increase in direct common stock ownership by a director may be perceived as a positive indicator of management's confidence and alignment with shareholder value.

Next Steps

• Continued vesting of the remaining 8,466 Restricted Stock Units held by David J. Mack, subject to his continued service as a Director.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, Form 4, Insider Transaction, David J. Mack, Restricted Stock Units, RSU Conversion, Common Stock, Director Ownership, SEC Filing